Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,155 | 575 | 93.1% |
| Education | $775.27 | 9 | 5.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $202.16 | 1 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,304 | 58 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,215 | 53 | $0 (2024) |
| Janssen Biotech, Inc. | $1,027 | 39 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $826.75 | 50 | $0 (2024) |
| Celgene Corporation | $754.77 | 24 | $0 (2024) |
| Genentech USA, Inc. | $659.04 | 16 | $0 (2024) |
| Gilead Sciences, Inc. | $612.05 | 28 | $0 (2024) |
| GlaxoSmithKline, LLC. | $517.18 | 20 | $0 (2024) |
| Incyte Corporation | $501.74 | 19 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $498.00 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,941 | 139 | Janssen Biotech, Inc. ($415.68) |
| 2023 | $2,515 | 91 | AstraZeneca Pharmaceuticals LP ($329.85) |
| 2022 | $2,976 | 141 | Janssen Biotech, Inc. ($381.14) |
| 2021 | $2,635 | 129 | Novartis Pharmaceuticals Corporation ($394.08) |
| 2020 | $902.47 | 44 | Merck Sharp & Dohme Corporation ($153.12) |
| 2019 | $1,728 | 36 | Celgene Corporation ($340.81) |
| 2018 | $262.11 | 3 | Celgene Corporation ($143.15) |
| 2017 | $171.93 | 2 | Genentech USA, Inc. ($97.67) |
All Payment Transactions
585 individual payment records from CMS Open Payments — Page 2 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $33.13 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: Oncology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.91 | General |
| 11/01/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.98 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: Oncology | ||||||
| 10/30/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $6.38 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $0.86 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: BioOncology | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.50 | General |
| 10/14/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $2.17 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $33.24 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $10.63 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $10.04 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: Immunology | ||||||
| 10/02/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $4.35 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: Oncology | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 441 | 861 | $135,160 | $58,903 |
| 2022 | 8 | 566 | 1,038 | $174,088 | $75,227 |
| 2021 | 10 | 531 | 936 | $148,948 | $67,507 |
| 2020 | 7 | 158 | 207 | $33,568 | $13,474 |
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 176 | 485 | $73,720 | $33,624 | 45.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 101 | 165 | $16,335 | $7,532 | 46.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 44 | 65 | $13,000 | $5,801 | 44.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 33 | $12,870 | $4,197 | 32.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 53 | $7,367 | $3,148 | 42.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 27 | 27 | $6,885 | $2,610 | 37.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 32 | 33 | $4,983 | $1,992 | 40.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 212 | 547 | $83,144 | $37,748 | 45.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 82 | 162 | $32,400 | $12,638 | 39.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 52 | 55 | $21,450 | $8,405 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 116 | 155 | $15,345 | $7,321 | 47.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 29 | 29 | $7,395 | $2,941 | 39.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 43 | $5,977 | $2,382 | 39.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 19 | 20 | $4,300 | $2,254 | 52.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 27 | 27 | $4,077 | $1,538 | 37.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 184 | 494 | $75,088 | $36,414 | 48.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 104 | 135 | $13,365 | $6,746 | 50.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 49 | 80 | $16,000 | $6,447 | 40.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 42 | 42 | $10,710 | $4,082 | 38.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 41 | 67 | $9,313 | $3,648 | 39.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 26 | 28 | $7,448 | $2,943 | 39.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 42 | 42 | $6,342 | $2,566 | 40.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $5,460 | $2,162 | 39.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 16 | $3,440 | $1,820 | 52.9% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Facility | 2021 | 18 | 18 | $1,782 | $681.56 | 38.2% |
About Dr. Nicholas Shuler, DO
Dr. Nicholas Shuler, DO is a Hematology & Oncology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2014. The National Provider Identifier (NPI) number assigned to this provider is 1790103513.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Shuler, DO has received a total of $14,132 in payments from pharmaceutical and medical device companies, with $2,941 received in 2024. These payments were reported across 585 transactions from 61 companies. The most common payment nature is "Food and Beverage" ($13,155).
As a Medicare-enrolled provider, Shuler has provided services to 1,696 Medicare beneficiaries, totaling 3,042 services with total Medicare billing of $215,112. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Kansas City, MO
- Active Since 03/29/2014
- Last Updated 07/24/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1790103513
Products in Payments
- KEYTRUDA (Biological) $1,304
- DARZALEX (Biological) $517.34
- JAKAFI (Drug) $459.09
- Trodelvy (Drug) $405.02
- OPDIVO (Biological) $401.08
- ERLEADA (Drug) $380.39
- IMBRUVICA (Drug) $364.57
- LIBTAYO (Biological) $364.53
- CALQUENCE (Drug) $357.85
- LYNPARZA (Drug) $288.45
- Lenvima (Drug) $274.77
- ELITEK (Biological) $269.35
- BLENREP (Biological) $259.29
- KISQALI (Drug) $250.22
- Abraxane (Drug) $250.00
- Revlimid (Drug) $226.39
- SARCLISA (Biological) $220.56
- TUKYSA (Drug) $207.31
- FOUNDATIONONE (Device) $202.16
- REBLOZYL (Biological) $187.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Kansas City
Dr. Suman Kambhampati, Md, MD
Hematology & Oncology — Payments: $281,918
Dr. Shahzad Raza, Md, MD
Hematology & Oncology — Payments: $184,113
Joseph Mcguirk, D.o, D.O
Hematology & Oncology — Payments: $129,700
Dr. Stephanie Graff, M.d, M.D
Hematology & Oncology — Payments: $120,151
Jaswinder Singh, Md, MD
Hematology & Oncology — Payments: $86,702
Dr. Tara Lin, Md, MD
Hematology & Oncology — Payments: $24,114